Goldman Sachs Group Inc Prelude Therapeutics Inc Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 155,215 shares of PRLD stock, worth $144,349. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,215
Previous 155,215 -0.0%
Holding current value
$144,349
Previous $119,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
BUY
$0.64 - $1.39 $4,408 - $9,575
6,889 Added 4.64%
155,215 $119,000
Q4 2024

Feb 11, 2025
BUY
$0.8 - $2.04 $42,532 - $108,456
53,165 Added 55.87%
148,326 $188,000
Q3 2024

Nov 14, 2024
BUY
$2.07 - $6.37 $41,892 - $128,916
20,238 Added 27.01%
95,161 $196,000
Q2 2024

Aug 13, 2024
BUY
$3.32 - $5.63 $24,886 - $42,202
7,496 Added 11.12%
74,923 $285,000
Q1 2024

May 15, 2024
SELL
$2.68 - $4.84 $5,461 - $9,863
-2,038 Reduced 2.93%
67,427 $319,000
Q4 2023

Feb 13, 2024
BUY
$1.69 - $4.37 $3,003 - $7,765
1,777 Added 2.63%
69,465 $296,000
Q3 2023

May 14, 2024
SELL
$2.74 - $4.79 $4,868 - $8,511
-1,777 Reduced 2.56%
67,688 $209,000
Q3 2023

Nov 14, 2023
BUY
$2.74 - $4.79 $120,286 - $210,281
43,900 Added 184.55%
67,688 $209,000
Q2 2023

May 14, 2024
SELL
$4.45 - $8.12 $114,400 - $208,748
-25,708 Reduced 51.94%
23,788 $107,000
Q2 2023

Aug 14, 2023
SELL
$4.45 - $8.12 $114,400 - $208,748
-25,708 Reduced 51.94%
23,788 $107,000
Q1 2023

May 14, 2024
BUY
$4.58 - $7.34 $154,492 - $247,592
33,732 Added 213.98%
49,496 $282,000
Q1 2023

May 11, 2023
BUY
$4.58 - $7.34 $154,492 - $247,592
33,732 Added 213.98%
49,496 $282,000
Q4 2022

May 14, 2024
SELL
$4.61 - $8.5 $27,526 - $50,753
-5,971 Reduced 27.47%
15,764 $95,000
Q4 2022

Feb 13, 2023
SELL
$4.61 - $8.5 $27,526 - $50,753
-5,971 Reduced 27.47%
15,764 $95,000
Q3 2022

May 14, 2024
SELL
$5.0 - $8.82 $112,800 - $198,979
-22,560 Reduced 50.93%
21,735 $144,000
Q3 2022

Nov 10, 2022
SELL
$5.0 - $8.82 $112,800 - $198,979
-22,560 Reduced 50.93%
21,735 $143,000
Q2 2022

May 14, 2024
SELL
$4.0 - $7.55 $100,680 - $190,033
-25,170 Reduced 36.23%
44,295 $232,000
Q2 2022

Aug 15, 2022
BUY
$4.0 - $7.55 $80,820 - $152,547
20,205 Added 83.87%
44,295 $232,000
Q1 2022

May 16, 2022
SELL
$6.9 - $13.22 $615,790 - $1.18 Million
-89,245 Reduced 78.74%
24,090 $166,000
Q4 2021

Feb 14, 2022
BUY
$11.89 - $31.74 $1.24 Million - $3.32 Million
104,676 Added 1208.87%
113,335 $1.41 Million
Q3 2021

Nov 10, 2021
BUY
$25.78 - $38.65 $223,229 - $334,670
8,659 New
8,659 $271,000

Others Institutions Holding PRLD

# of Institutions
57
Shares Held
28.3M
Call Options Held
23.9K
Put Options Held
0
View Full List

About Prelude Therapeutics Inc

PRLD Quotes by TradingView
  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $33.8M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email